Cargando…

Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia

The 2013 American College of Cardiology/American Heart Association guidelines on cholesterol management placed greater emphasis on statin therapy given the well-established benefits in primary and secondary prevention of cardiovascular disease. Residual risk may remain after statin initiation, in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benes, Lane B, Bassi, Nikhil S, Davidson, Michael H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5161399/ https://www.ncbi.nlm.nih.gov/pubmed/28003756 http://dx.doi.org/10.2147/VHRM.S58149

Ejemplares similares

Comparison of efficacy and safety of combination therapy with statins and omega-3 fatty acids versus statin monotherapy in patients with dyslipidemia: A systematic review and meta-analysis
por: Choi, Hye Duck, et al.
Publicado: (2018)

Efficacy of Statin Monotherapy or in Combination With Coenzyme A Capsule in Patients With Metabolic Syndrome and Mixed Dyslipidemia
por: Lai, Jiangtao, et al.
Publicado: (2015)

Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid
por: Moutzouri, Elisavet, et al.
Publicado: (2010)

Recent findings on the health effects of omega-3 fatty acids and statins, and their interactions: do statins inhibit omega-3?
por: de Lorgeril, Michel, et al.
Publicado: (2013)

Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial
por: Dunbar, Richard L., et al.
Publicado: (2015)

Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy
por: Lee, Jun-beom, et al.
Publicado: (2017)

Statin/ezetimibe combination therapy vs statin monotherapy for carotid atherosclerotic plaque inflammation
por: Oh, Minyoung, et al.
Publicado: (2021)

Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia
por: Alagona, Peter
Publicado: (2010)

The role of dyslipidemia and statins in venous thromboembolism
por: Ray, Joel G, et al.
Publicado: (2001)

Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia
por: Mindrescu, Catalin, et al.
Publicado: (2008)

Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Comparative Efficacy and Safety of Statin Monotherapy and Statin plus Ezetimibe Combination in a Real-World Setting
por: Ezhov, Marat V., et al.
Publicado: (2023)

The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)

New Drugs for Treating Dyslipidemia: Beyond Statins
por: Ahn, Chang Ho, et al.
Publicado: (2015)

Comparison of Renal Effects of Ezetimibe–Statin Combination versus Statin Monotherapy: A Propensity-Score-Matched Analysis
por: Bae, Jaehyun, et al.
Publicado: (2020)

A Revision on the Effectiveness of Omega-3 Polyunsaturated Fatty Acids as Monotherapy in the Treatment of Major Depressive Disorder
por: Accinni, Tommaso, et al.
Publicado: (2022)

Prevalence and types of persistent dyslipidemia in patients treated with statins
por: Reiner, Željko, et al.
Publicado: (2013)

Factors influencing dyslipidemia in statin-treated patients in Lebanon and Jordan: results of the Dyslipidemia International Study
por: Azar, Sami T, et al.
Publicado: (2014)

Statin treatment alters serum n-3 to n-6 polyunsaturated fatty acids ratio in patients with dyslipidemia
por: Nozue, Tsuyoshi, et al.
Publicado: (2015)

Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation
por: Iverson, Cory, et al.
Publicado: (2018)

Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia
por: Kumar, Shoba Sujana, et al.
Publicado: (2009)

Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study
por: Crandell, James R.
Publicado: (2016)

Evidence on Statins, Omega-3, and Prostate Cancer: A Narrative Review
por: Kim, Hwanik, et al.
Publicado: (2022)

Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
por: Bak, Keunhyeong, et al.
Publicado: (2023)

Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
por: Lee, Jeongmin, et al.
Publicado: (2023)

Cardiovascular Events in Patients Received Combined Fibrate/Statin Treatment versus Statin Monotherapy: Acute Coronary Syndrome Israeli Surveys Data
por: Tenenbaum, Alexander, et al.
Publicado: (2012)

The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy
por: Ikegami, Yuichi, et al.
Publicado: (2018)

Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature
por: Yu, Min, et al.
Publicado: (2020)

Effect and safety of combination lipid‐lowering therapies based on statin treatment versus statin monotherapies on patients with high risk of cardiovascular events
por: Wang, Chunli, et al.
Publicado: (2018)

Effectiveness and safety of combinational therapy compared with intensified statin monotherapy in patients with coronary heart disease
por: Liu, Chenghua, et al.
Publicado: (2018)

Omega-3 Fatty acids as Monotherapy in Treating Depression in Pregnant Women: a Meta- Analysis of Randomized Controlled Trials
por: Wei-Hong, Liu, et al.
Publicado: (2017)

Effect of Omega-3 Fatty Acid Ethyl Esters on the Oxylipin Composition of Lipoproteins in Hypertriglyceridemic, Statin-Treated Subjects
por: Newman, John W., et al.
Publicado: (2014)

Treatment of Statin-Induced Necrotizing Autoimmune Myopathy With Glucocorticoid Monotherapy
por: Lempel, Matthew, et al.
Publicado: (2020)

Association Between Omega‐3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose–Response Meta‐Analysis of Randomized Controlled Trials
por: Wang, Tianjiao, et al.
Publicado: (2023)

Omega 3 Fatty Acids vs Omega 6 Fatty Acids
por: Feliu, María, et al.
Publicado: (2022)

Associations between Statin/Omega3 Usage and MRI-Based Radiomics Signatures in Prostate Cancer
por: Shi, Yu, et al.
Publicado: (2021)

The effect of omega-3 fatty acids and its combination with statins on lipid profile in patients with hypertriglyceridemia: A systematic review and meta-analysis of randomized controlled trials
por: Yang, Yunjiao, et al.
Publicado: (2022)

Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins
por: Tenenbaum, Alexander, et al.
Publicado: (2006)

The Effects of Fenofibric Acid Alone and With Statins on the Prevalence of Metabolic Syndrome and Its Diagnostic Components in Patients With Mixed Dyslipidemia
por: Bays, Harold E., et al.
Publicado: (2010)

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs
por: Caldwell, Stephen
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vr1jn06on6fvo9kopvpbj927v4